CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Xingjuan Chao filed a notice of intent to sell 39,000 shares of common stock of CBLL through Fidelity Brokerage Services, with an aggregate market value of $702,000.00. The filing notes total common shares outstanding of 37,942,700 and links the sale to stock option exercises.
Over the prior three months, Chao reported multiple sales of common stock, including 39,000 shares for $784,000.03, 6,030 shares for $108,515.27, 39,000 shares for $714,855.81, and 39,000 shares for $776,162.92, as well as option exercises for 14,000 and 25,000 shares.
Ceribell, Inc. filed an initial statement of beneficial ownership for Thomas A. West, identifying him as a director of the company. He is not listed as an officer or a ten percent owner in this filing.
This submission reports no insider transactions and notes an exhibit titled Power of Attorney authorizing certain filing actions.
West Thomas A. reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. director Thomas A. West received an equity grant of 16,011 shares of Common Stock in the form of restricted stock units (RSUs) on 2026-07-28. The award was reported at a per-share price of $0.00, and his directly held position after this grant is 16,011 shares, all from this RSU award.
O'KEEFE SHARON reported acquisition or exercise transactions in this Form 4 filing.
Ceribell, Inc. director Sharon O'Keefe received a grant of 16,011 restricted stock units (RSUs) representing common stock on July 28, 2026. The award was reported at a price of $0.00 per unit and results in total direct holdings of 16,011 RSUs after the transaction.
Ceribell, Inc. filed an initial Form 3 identifying Sharon O’Keefe as a director. The filing lists her as a reporting person under SEC beneficial ownership rules but shows no insider transactions or derivative positions and does not disclose any specific share holdings.
CeriBell, Inc. adjusted its board structure effective July 28, 2026. To achieve a more balanced membership among director classes, the board accepted the resignations of William W. Burke and Joseph M. Taylor as Class I directors and immediately re-elected them as Class II and Class III directors, respectively, with their service otherwise deemed uninterrupted.
On the same date, the authorized board size increased from seven to nine directors, and Sharon L. O’Keefe and Thomas A. West were elected as Class I directors. O’Keefe joined the Compensation Committee and West joined the Audit Committee. Each new non-employee director will receive annual cash compensation and restricted stock units under the company’s Non-Employee Director Compensation Program, plus an initial restricted stock unit award based on dividing $300,000 by the average closing price over the most recent 30 trading days, vesting in three equal annual installments. The company will also enter into standard indemnification agreements with both, and there are no related-party arrangements or interests requiring disclosure.
BlackRock, Inc. reports beneficial ownership of common stock of CERIBELL INC. BlackRock and certain of its business units collectively hold 1,909,628 shares, representing 5.03% of Ceribell’s outstanding common stock. These holdings are reported on a passive Schedule 13G basis.
BlackRock has sole voting power over 1,877,292 shares and sole dispositive power over 1,909,628 shares, with no shared voting or dispositive power. Various underlying clients and accounts have economic interests in these shares, but no single person has more than five percent of Ceribell’s total outstanding common shares.
Ceribell, Inc. President and CEO Xingjuan Chao reported an exercise-and-sell transaction in Common Stock. On July 7, 2026, she exercised stock options to acquire a total of 25,000 shares at an exercise price of $4.70 per share and sold 39,000 shares of Common Stock in open-market transactions at a weighted average price of $19.90 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. Following the transactions, she directly holds 802,317 shares of Common Stock and may be deemed to share beneficial ownership of 369,088 shares held indirectly through the ACP 2021 Trust. The stock option referenced in the filing is fully vested and currently exercisable.
CBLL notice describes proposed and recent sales of Common Stock by a holder and option-related sales. The record lists a 39,000 share entry tied to Fidelity Brokerage Services LLC with $780,000.00 and an effective date of 07/07/2026. The filing also records option-related sales dated 05/15/2025 (14,000 shares) and 07/07/2026 (25,000 shares) labeled "Stock Option Exercise" and cash settlements. Separately, Xingjuan Chao sold Common Stock in three reported transactions: 39,000 shares on 05/05/2026 for $784,000.03, 6,030 shares on 05/21/2026 for $108,515.27, and 39,000 shares on 06/08/2026 for $714,855.81.
Ceribell, Inc. director William W. Burke reported an open-market sale of 2,207 shares of Common Stock at a price of $19.84 per share. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person. After this sale, Burke directly holds 23,022 Ceribell shares, indicating he retains a substantial ongoing equity position in the company.